Evidence map›Paper›PMID 26464195›Full record

ArticleCarcinogenesis2015

The retinoic acid derivative, ABPN, inhibits pancreatic cancer through induction of Nrdp1.

Sanguine Byun, Seung Ho Shin, Eunjung Lee, Jihoon Lee, Sung-Young Lee, Lee Farrand, Sung Keun Jung, Yong-Yeon Cho, Soo-Jong Um, Hong-Sig Sin and 7 more

Abstract read
In one paragraph

Article in Carcinogenesis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Significance of Vitamins A and E in Cancer Progression and Prevention.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 4 countries.

Sanguine ByunDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN 55912, USA, Department of Agricultural Biotechnology, Seoul National University, Advanced Institutes of Convergence Technology, Seoul National University, Seoul 151-742, Republic of Korea.
Seung Ho ShinDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN 55912, USA, Program in Biomedical Informatics and Computational Biology, University of Minnesota, Minneapolis, MN 55454, USA.
Eunjung LeeDepartment of Agricultural Biotechnology, Seoul National University, Traditional Alcoholic Beverage Research Team, Korea Food Research Institute, Seongnam, Republic of Korea.
Jihoon LeeDepartment of Agricultural Biotechnology, Seoul National University.
Sung-Young LeeDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Lee FarrandDepartment of Agricultural Biotechnology, Seoul National University, Yuhan Research Institute, Yuhan Corporation, Giheung-gu, Yongin-si 416-1, Republic of Korea.
Sung Keun JungDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Yong-Yeon ChoDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Soo-Jong UmDepartment of Bioscience and Biotechnology/Institute of Bioscience, BK21 Graduate Program, Sejong University, Seoul, Republic of Korea, CheBiGen Inc, BioPark infrastructure BI. Business, 452-79 Jang-Dong, Jeonju, Jeollabukdo, Republic of Korea.
Hong-Sig SinCheBiGen Inc, BioPark infrastructure BI. Business, 452-79 Jang-Dong, Jeonju, Jeollabukdo, Republic of Korea.
Youn-Ja KwonCheBiGen Inc, BioPark infrastructure BI. Business, 452-79 Jang-Dong, Jeonju, Jeollabukdo, Republic of Korea.
Chengjuan ZhangDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN 55912, USA, Department of Molecular Pathology, The Affiliated Cancer Hospital, Zhengzhou University, Zhengzhou, China and.
Benjamin K TsangDepartment of Agricultural Biotechnology, Seoul National University, Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Canada.
Ann M BodeDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Hyong Joo LeeDepartment of Agricultural Biotechnology, Seoul National University, Advanced Institutes of Convergence Technology, Seoul National University, Seoul 151-742, Republic of Korea.
Ki Won LeeDepartment of Agricultural Biotechnology, Seoul National University, Advanced Institutes of Convergence Technology, Seoul National University, Seoul 151-742, Republic of Korea.
Zigang DongDepartment of Cellular and Molecular Biology, The Hormel Institute, University of Minnesota, Austin, MN 55912, USA, zgdong@hi.umn.edu.
Hormel (United States) · USSeoul National University · KRUniversity of Minnesota · USAdvanced Institute of Convergence Technology · KRKorea Food Research Institute · KRSejong University · KRYuhan University · KR

Funding

Developing new ornithine decarboxylase inhibitors to prevent skin & colon cancerR01CA166011 · NCI · UNIVERSITY OF MINNESOTA · PI DONG, ZIGANG · 2013 to 2017
$1.6M
Anticarcinogenic Mechanisms of Tea ConstituentsR37CA081064 · NCI · UNIVERSITY OF MINNESOTA · PI DONG, ZIGANG · 2008 to 2012
$1.5M
Molecular Mechanisms and Targets of Soy Compounds in the Prevention of Colon CancR21CA172457 · NCI · UNIVERSITY OF MINNESOTA · PI DONG, ZIGANG · 2013 to 2014
$327k
NCI NIH HHS CA166011NCI NIH HHS CA172457NCI NIH HHS R37 CA081064
6 · The paper itself

Abstract

Combination chemotherapy for the treatment of pancreatic cancer commonly employs gemcitabine with an EGFR inhibitor such as erlotinib. Here, we show that the retinoic acid derivative, ABPN, exhibits more potent anticancer effects than erlotinib, while exhibiting less toxicity toward noncancerous human control cells. Low micromolar concentrations of ABPN induced apoptosis in BxPC3 and HPAC pancreatic cancer cell lines, concomitant with a reduction in phosphorylated EGFR as well as decreased ErbB3, Met and BRUCE protein levels. The degradation of ErbB3 is a result of proteasomal degradation, possibly due to the ABPN-dependent upregulation of Nrdp1. Administration of ABPN showed significant reductions in tumor size when tested using a mouse xenograft model, with higher potency than erlotinib at the same concentration. Analysis of the tumors demonstrated that ABPN treatment suppressed ErbB3 and Met and induced Nrdp1 in vivo. The data suggest that ABPN may be more suitable in combination chemotherapy with gemcitabine than the more widely used EGFR inhibitor, erlotinib.

Indexed as

AnimalsAntineoplastic AgentsApoptosisCell Line, TumorDeoxycytidineDrug SynergismErlotinib HydrochlorideFluorouracilGemcitabineHumansMaleMice, NudePancreatic NeoplasmsProteasome Endopeptidase ComplexProteolysisProto-Oncogene Proteins c-met4-amino-2-(butyrylamino)phenyl(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraenoateAntineoplastic AgentsDeoxycytidineERBB3 protein, humanErlotinib HydrochlorideFluorouracilGemcitabineMET protein, humanProteasome Endopeptidase ComplexProto-Oncogene Proteins c-metReceptor, ErbB-3RetinoidsRNF41 protein, humanTretinoinUbiquitin-Protein Ligases

Identifiers

PMID26464195
PMCPMC4850933
OpenAlexW2241247270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.